Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals.

Literature DB >> 27238443

Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals.

Bo Sun¹, Maie S Taha², Benjamin Ramsey³, Sandra Torregrosa-Allen³, Bennett D Elzey⁴, Yoon Yeo⁵.

Abstract

Intraperitoneal (IP) chemotherapy is a promising post-surgical therapy of ovarian cancer, but the full potential is yet to be realized. To facilitate IP chemotherapy of ovarian cancer, we developed an in-situ crosslinkable hydrogel depot containing paclitaxel (PTX) nanocrystals (PNC). PNC suppressed SKOV3 cell proliferation more efficiently than microparticulate PTX precipitates (PPT), and the gel containing PNC (PNC-gel) showed a lower maximum tolerated dose than PPT-containing gel (PPT-gel) in mice, indicating greater dissolution and cellular uptake of PNC than PPT. A single IP administration of PNC-gel extended the survival of tumor-bearing mice significantly better than Taxol, but PPT-gel did not. These results support the advantage of PNC over PPT and demonstrate the promise of a gel depot as an IP drug delivery system.

Entities: CellLine Chemical Disease Gene Mutation Species

Keywords: Drug delivery; Hydrogel depot; Intraperitoneal chemotherapy; Nanocrystals; Ovarian cancer

Mesh：

Substances：

Year: 2016 PMID： 27238443 PMCID： PMC5310690 DOI： 10.1016/j.jconrel.2016.05.056

Source DB: PubMed Journal: J Control Release ISSN： 0168-3659 Impact factor: 9.776

39 in total

1. Development of a new method to assess nanocrystal dissolution based on light scattering.

Authors: Katharina Anhalt; Simon Geissler; Meike Harms; Markus Weigandt; Gert Fricker
Journal: Pharm Res Date: 2012-06-12 Impact factor: 4.200

2. A simple in vitro model to study the release kinetics of liposome encapsulated material.

Authors: R Peschka; C Dennehy; F C Szoka
Journal: J Control Release Date: 1998-12-04 Impact factor: 9.776

3. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.

Authors: Setsuko K Chambers; H-H Sherry Chow; Mike F Janicek; Janiel M Cragun; Kenneth D Hatch; Haiyan Cui; Cynthia Laughren; Mary C Clouser; Janice L Cohen; Heather M Wright; Nisreen Abu Shahin; David S Alberts
Journal: Clin Cancer Res Date: 2012-03-15 Impact factor: 12.531

Review 4. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

Authors: Csilla Hasovits; Stephen Clarke
Journal: Clin Pharmacokinet Date: 2012-04-01 Impact factor: 6.447

5. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

Authors: D S Alberts; P Y Liu; E V Hannigan; R O'Toole; S D Williams; J A Young; E W Franklin; D L Clarke-Pearson; V K Malviya; B DuBeshter
Journal: N Engl J Med Date: 1996-12-26 Impact factor: 91.245

6. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.

Authors: E Lengyel; B Schmalfeldt; E Konik; K Späthe; K Härting; A Fenn; U Berger; R Fridman; M Schmitt; D Prechtel; W Kuhn
Journal: Gynecol Oncol Date: 2001-08 Impact factor: 5.482

7. Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer.

Authors: Hyunah Cho; Tsz Chung Lai; Glen S Kwon
Journal: J Control Release Date: 2012-12-13 Impact factor: 9.776

8. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.

Authors: Pierre Marchettini; O Anthony Stuart; Faheez Mohamed; Dal Yoo; Paul H Sugarbaker
Journal: Cancer Chemother Pharmacol Date: 2002-04-26 Impact factor: 3.333

9. Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles.

Authors: Emily Gullotti; Joonyoung Park; Yoon Yeo
Journal: Pharm Res Date: 2013-04-23 Impact factor: 4.200

10. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.

Authors: Tao Yang; Fu-De Cui; Min-Koo Choi; Jei-Won Cho; Suk-Jae Chung; Chang-Koo Shim; Dae-Duk Kim
Journal: Int J Pharm Date: 2007-02-13 Impact factor: 5.875

8 in total

1. Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.

Authors: Smrithi Padmakumar; Neha N Parayath; Shantikumar V Nair; Deepthy Menon; Mansoor M Amiji
Journal: J Control Release Date: 2019-05-17 Impact factor: 9.776

2. Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.

Authors: Neha N Parayath; Srujan Kumar Gandham; Fraser Leslie; Mansoor M Amiji
Journal: Cancer Lett Date: 2019-07-06 Impact factor: 8.679

3. Surface-fill hydrogel attenuates the oncogenic signature of complex anatomical surface cancer in a single application.

Authors: Poulami Majumder; Anand Singh; Ziqiu Wang; Kingshuk Dutta; Roma Pahwa; Chen Liang; Caroline Andrews; Nimit L Patel; Junfeng Shi; Natalia de Val; Scott T R Walsh; Albert Byungyun Jeon; Baktiar Karim; Chuong D Hoang; Joel P Schneider
Journal: Nat Nanotechnol Date: 2021-09-23 Impact factor: 40.523

4. Sustained Delivery of Carfilzomib by Tannic Acid-Based Nanocapsules Helps Develop Antitumor Immunity.

Authors: Maie S Taha; Gregory M Cresswell; Joonyoung Park; Wooin Lee; Timothy L Ratliff; Yoon Yeo
Journal: Nano Lett Date: 2019-11-04 Impact factor: 11.189

5. Thermosensitive Injectable Hydrogel for Simultaneous Intraperitoneal Delivery of Doxorubicin and Prevention of Peritoneal Adhesion.

Authors: Chih-Hao Chen; Chang-Yi Kuo; Shih-Hsien Chen; Shih-Hsuan Mao; Chih-Yen Chang; K T Shalumon; Jyh-Ping Chen
Journal: Int J Mol Sci Date: 2018-05-04 Impact factor: 5.923